Propanc Biopharma, Inc.

PPCB

US74346N6022

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 11:15:30 2024-07-17 EDT			5-day change	1st Jan Change
0.0009 ^USD	+12.50%		+12.50%	-92.50%

06-25	Propanc Biopharma, Inc. Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office	CI
06-20	Propanc Biopharma, Inc. announced that it has received $0.03375 million in funding	CI

Propanc Biopharma, Inc. announced that it has received $0.51 million in funding from Eagle Equities, LLC

January 01, 2018

On January 2, 2018 Propanc Biopharma, Inc. (OTCPK:PPCB) closed the transaction.

Latest news about Propanc Biopharma, Inc.

Propanc Biopharma, Inc. Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office	06-25	CI
Propanc Biopharma, Inc. announced that it has received $0.03375 million in funding	06-19	CI
Propanc Biopharma, Inc. announced that it has received $0.041 million in funding from 1800 Diagonal Lending, LLC	06-16	CI
Propanc Biopharma, Inc. Enters into and Closed a Loan Agreement with an Investor	06-13	CI
Propanc Biopharma, Inc. announced that it has received $0.041 million in funding from 1800 Diagonal Lending, LLC	05-30	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-15	CI
Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office	04-16	CI
Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC	04-15	CI
Propanc Biopharma, Inc. announced that it has received $0.046875 million in funding	02-29	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-20	CI
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office	01-16	CI
Propanc Biopharma, Inc. announced that it has received $0.135 million in funding	12-10	CI
Propanc Biopharma, Inc. announced that it has received $0.045 million in funding	12-03	CI
Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-14	CI
Propanc Biopharma, Inc. announced that it has received $0.04 million in funding	23-10-28	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.04 million in funding	23-10-19	CI
Propanc Biopharma, Inc. announced that it has received $0.0575 million in funding from GS Capital Partners LLC	23-10-15	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.0575 million in funding from GS Capital Partners LLC	23-10-11	CI
Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-28	CI
Propanc Biopharma, Inc. announced that it has received $0.055 million in funding	23-08-30	CI
Propanc Biopharma, Inc. announced that it has received $0.12 million in funding	23-08-29	CI
Propanc Biopharma, Inc. announced that it has received $0.0725 million in funding from GS Capital Partners LLC	23-08-22	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.055 million in funding	23-08-15	CI
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia	23-08-15	CI
Propanc Biopharma, Inc. announced that it expects to receive $0.12 million in funding	23-08-14	CI

Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PROPANC BIOPHARMA, INC.	-92.50%	266K
VERTEX PHARMACEUTICALS INCORPORATED	+17.96%	126B
REGENERON PHARMACEUTICALS, INC.	+22.91%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.75%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-15.01%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.21%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.20%	14.08B